MMM 3M CO
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 66740 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.7%
TTM net income YoY4.0%
TTM EPS YoY7.0%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin39.5%
Operating margin18.8%
Net margin14.0%
FCF margin10.6%
EBITDA margin24.4%
Returns
ROE80.8%
ROA9.2%
ROIC (approx.)28.5%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets87.0%
Debt / equity3.63x
Current ratio1.41x
Interest coverage5.54x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio-0.2%
Payout ratio45.3%
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $24.95B | $24.57B |
| Cost of revenue | $14.99B | $14.45B |
| Gross profit | $9.96B | $10.13B |
| R&D expense | — | $700.00M |
| SG&A expense | $4.00B | $4.22B |
| Operating income | $4.63B | $4.82B |
| Interest expense | $946.00M | $1.19B |
| Pretax income | $4.21B | $4.82B |
| Income tax | $1.00B | $804.00M |
| Net income | $3.25B | $4.17B |
| EBITDA | $5.94B | $6.18B |
| EPS (basic) | 6.05 | 7.58 |
| EPS (diluted) | 6.00 | 7.55 |
| Dividends declared per share | 2.92 | 3.61 |
| Weighted avg. shares (diluted) | 541.30M | 552.40M |
| Balance sheet | ||
| Cash & equivalents | $5.24B | $5.60B |
| Receivables | $3.53B | $3.19B |
| Inventory | $3.66B | $3.70B |
| Current assets | $16.39B | $15.88B |
| PP&E, net | $7.10B | $7.39B |
| Goodwill | $6.42B | $6.28B |
| Intangibles | $1.10B | $1.21B |
| Total assets | $37.73B | $39.87B |
| Current liabilities | $9.60B | $11.26B |
| Short-term debt | $1.67B | $1.92B |
| Long-term debt | $10.93B | $11.12B |
| Total debt | $12.60B | $13.04B |
| Total liabilities | $32.99B | $35.97B |
| Shareholders' equity | $4.70B | $3.84B |
| Net debt | $7.37B | $7.44B |
| Shares outstanding | 530.28M | 539.47M |
| Cash flow statement | ||
| Operating cash flow | $2.31B | $1.82B |
| Capital expenditure | $910.00M | $1.18B |
| Free cash flow | $1.40B | $638.00M |
| Investing cash flow | $1.35B | -$3.21B |
| Financing cash flow | -$4.02B | $1.10B |
| Depreciation & amortization | $1.31B | $1.36B |
| Stock-based compensation | $225.00M | $289.00M |
| Dividends paid | $1.56B | $1.98B |
| Share buybacks | $3.25B | $1.80B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.